Opko Health Inc (NYSE:OPK) stated gains of 4,856,453 shares or 7.4% in the short interest. The short interest registered from 65,756,912 on May 31,2016 to 70,613,365 on June 15,2016. In terms of floated shares, the shorted positions stood at 21.6%. The stock has been averaging 3,828,164 shares daily in trading and would need 18 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Opko Health Inc (NYSE:OPK): The stock opened at $9.38 on Friday but the bulls could not build on the opening and the stock topped out at $9.58 for the day. The stock traded down to $9.30 during the day, due to lack of any buying support eventually closed down at $9.46 with a loss of -2.97% for the day. The stock had closed at $9.75 on the previous day. The total traded volume was 5,439,416 shares.
The company shares have dropped -37.06% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $17.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $9.87 and the 200 Day Moving Average price is recorded at $9.74.
Stocks of Opko Health Inc (NYSE:OPK) rallied by 4.53% during the past week but lost 9.21% on a 4-week basis. The company has outperformed the S&P 500 by 6.27% in the past week but underperformed the index by 6.47% in the last 4 weeks.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.